Peptide Vaccination Against Cancer Testis Antigens in Combination With Azacitidine for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia

an ongoing phase I study

S. Holmberg, A. Ortved Gang, I.M. Svane, I. Høgh Dufva, Sine Reker Hadrup

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Abstract

Myelodysplastic Syndrome (MDS) is a clonal disorder and characterized by increasing bone marrow failure due to accumulation of genetic and epigenetic changes in hematopoietic stem cells. Patients with high-risk disease have a poor prognosis and a high risk of progression to Acute Myeloid Leukemia (AML). The dysplastic cells harbor chromosomal breakage, point mutations and promoter hyper-methylation of tumor suppressor genes.For most patients, who are not eligible for bone marrow transplantation, hypomethylating agents, such as azacitidine (AZA), are currently the only treatment option. The demand for more effective therapies in this patient group is huge. Though the mechanism of AZA is not fully elucidated re-expression of tumor suppressor genes can serve as a mechanism for growth arrest. In addition, there is accumulating evidence for an up-regulation of cancer testis antigens (CTA), which could lead to increased immune recognition of tumor cells and immune-mediated tumor cell killing. CTA’s are known to be immunogenic and are only expressed at immunoprivileged sites and on malignant cells, making them attractive as targets for therapeutic cancer vaccination.
Original languageEnglish
Article numberPB1915
JournalHaematologica
Volume101
Issue numberS1
Pages (from-to)771-772
Number of pages2
ISSN0390-6078
Publication statusPublished - 2016
Event21st Congress of the European Hematology Association - Copenhagen, Denmark
Duration: 9 Jun 201612 Jun 2016
http://www.ehaweb.org/congress-and-events/21st-congress/key-information-3/

Conference

Conference21st Congress of the European Hematology Association
CountryDenmark
CityCopenhagen
Period09/06/201612/06/2016
Internet address

Cite this

@article{476efbe5ae514684aa027b1170c5b4c1,
title = "Peptide Vaccination Against Cancer Testis Antigens in Combination With Azacitidine for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia: an ongoing phase I study",
abstract = "Myelodysplastic Syndrome (MDS) is a clonal disorder and characterized by increasing bone marrow failure due to accumulation of genetic and epigenetic changes in hematopoietic stem cells. Patients with high-risk disease have a poor prognosis and a high risk of progression to Acute Myeloid Leukemia (AML). The dysplastic cells harbor chromosomal breakage, point mutations and promoter hyper-methylation of tumor suppressor genes.For most patients, who are not eligible for bone marrow transplantation, hypomethylating agents, such as azacitidine (AZA), are currently the only treatment option. The demand for more effective therapies in this patient group is huge. Though the mechanism of AZA is not fully elucidated re-expression of tumor suppressor genes can serve as a mechanism for growth arrest. In addition, there is accumulating evidence for an up-regulation of cancer testis antigens (CTA), which could lead to increased immune recognition of tumor cells and immune-mediated tumor cell killing. CTA’s are known to be immunogenic and are only expressed at immunoprivileged sites and on malignant cells, making them attractive as targets for therapeutic cancer vaccination.",
author = "S. Holmberg and {Ortved Gang}, A. and I.M. Svane and {H{\o}gh Dufva}, I. and Hadrup, {Sine Reker}",
year = "2016",
language = "English",
volume = "101",
pages = "771--772",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "S1",

}

Peptide Vaccination Against Cancer Testis Antigens in Combination With Azacitidine for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia : an ongoing phase I study. / Holmberg, S.; Ortved Gang, A.; Svane, I.M.; Høgh Dufva, I.; Hadrup, Sine Reker.

In: Haematologica, Vol. 101, No. S1, PB1915, 2016, p. 771-772.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

TY - ABST

T1 - Peptide Vaccination Against Cancer Testis Antigens in Combination With Azacitidine for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia

T2 - an ongoing phase I study

AU - Holmberg, S.

AU - Ortved Gang, A.

AU - Svane, I.M.

AU - Høgh Dufva, I.

AU - Hadrup, Sine Reker

PY - 2016

Y1 - 2016

N2 - Myelodysplastic Syndrome (MDS) is a clonal disorder and characterized by increasing bone marrow failure due to accumulation of genetic and epigenetic changes in hematopoietic stem cells. Patients with high-risk disease have a poor prognosis and a high risk of progression to Acute Myeloid Leukemia (AML). The dysplastic cells harbor chromosomal breakage, point mutations and promoter hyper-methylation of tumor suppressor genes.For most patients, who are not eligible for bone marrow transplantation, hypomethylating agents, such as azacitidine (AZA), are currently the only treatment option. The demand for more effective therapies in this patient group is huge. Though the mechanism of AZA is not fully elucidated re-expression of tumor suppressor genes can serve as a mechanism for growth arrest. In addition, there is accumulating evidence for an up-regulation of cancer testis antigens (CTA), which could lead to increased immune recognition of tumor cells and immune-mediated tumor cell killing. CTA’s are known to be immunogenic and are only expressed at immunoprivileged sites and on malignant cells, making them attractive as targets for therapeutic cancer vaccination.

AB - Myelodysplastic Syndrome (MDS) is a clonal disorder and characterized by increasing bone marrow failure due to accumulation of genetic and epigenetic changes in hematopoietic stem cells. Patients with high-risk disease have a poor prognosis and a high risk of progression to Acute Myeloid Leukemia (AML). The dysplastic cells harbor chromosomal breakage, point mutations and promoter hyper-methylation of tumor suppressor genes.For most patients, who are not eligible for bone marrow transplantation, hypomethylating agents, such as azacitidine (AZA), are currently the only treatment option. The demand for more effective therapies in this patient group is huge. Though the mechanism of AZA is not fully elucidated re-expression of tumor suppressor genes can serve as a mechanism for growth arrest. In addition, there is accumulating evidence for an up-regulation of cancer testis antigens (CTA), which could lead to increased immune recognition of tumor cells and immune-mediated tumor cell killing. CTA’s are known to be immunogenic and are only expressed at immunoprivileged sites and on malignant cells, making them attractive as targets for therapeutic cancer vaccination.

M3 - Conference abstract in journal

VL - 101

SP - 771

EP - 772

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - S1

M1 - PB1915

ER -